Metastatic cancer of unknown primary site (CUP) represents a heterogeneous group of tumors. Diagnosis is made by a biopsy of a metastatic lesion. CUP accounts for 2-3% of all malignancies. It is defined by the presence of metastatic disease for which a primary site is undetectable on presentation. Clinical presentations, histological appearances and natural histories vary widely explaining why it is impossible to define a common radio-diagnostic approach to all patients. Some specific clinical presentations will guide directly the diagnostic work-up. History, physical examination, histology of the metastases and tumor markers can sometimes suggest the primary or a specific clinico-pathological entity. Radio-imaging investigations are only part of an integrated approach aiming to find the primary and to define the best treatment for the patient. Consequently, although this review should focus on radio-imaging investigations, we have to discuss also several other issues directly related to this topic. We hope that the reader accept that our review on radio-imaging investigations reflects this integrated approach because discussing imaging techniques only outside of this clinical context does not allow to give any useful recommendation about the best use of imaging techniques in CUP. We will avoid reporting in detail the sensitivity and specificity of imaging techniques. The methodology used to evaluate the accuracy of imaging techniques is rather poor in many publications (retrospective evaluation, description of study population, description of gold standard etc.). The heterogeneity of the study population and the definition of the gold standard (autopsy, other imaging techniques, follow-up etc.) have major impact on the results. The definition of CUP has changed over time. In the past, some researchers argued that the diagnosis of CUP could be made only if the primary tumor was not found at autopsy. Now we define that CUP represents a group of metastatic tumors for which no primary site can be detected following a thorough medical history, careful clinical examination and extensive diagnostic work-up. Consequently, the amount of work-up that has been done before accepting the diagnosis of CUP is an important factor. More importantly, only a few investigators have been interested in detailed studies of these patients. Past information suffers from many generalizations and is not representative of the entire patient population or specific subgroups of patients. Furthermore, the sensitivity of all imaging techniques has rapidly increased over time with technical improvements. On the other hand, pathological evaluation of the metastasis with recent immunohistochemical markers allows more frequently the identification of the primary. Consequently, results published 10 or 20 years ago give not much useful information on the impact of imaging techniques in patient management in 2006. Unfortunately, the false positive rate of some imaging procedures equalled or exceeded the true positive rate [1] . Extensive work-up with modern imaging technology such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) has resulted in some improvements in diagnosis, showing sometimes the primary and allowing a better definition of the extent of the disease. For example, in retrospective studies from the Mayo Clinic and the University of Kansas, CT of the abdomen and/or chest was able to correctly identify the primary tumor in 35% and 32% of patients, respectively [2, 3] . However, the primary remains unknown in many patients, even on autopsy. Autopsies performed between 1984 and 1999 at the Mayo Clinic in 64 patients without primary tumor identified during the patient's lifetime showed the primary site in 35 patients (55%). Common primary tumor locations were the lung, the pancreaticobiliary system and the upper and lower gastrointestinal tract [4] . The detection rate was lowest among the poorly differentiated carcinomas.
clinical presentation
Patients usually present symptoms related to the localization of the metastases and constitutional symptoms including anorexia, weight loss, weakness and fatigue. Physical examination frequently reveals peripheral adenopathy, pleural effusions, ascites and hepatomegaly. Common sites of metastatic spread are the lung, the liver and the bones. Unfortunately, the overall survival for this patient population remains poor with a median survival time of 11 months and only an 11% 5-year survival rate [5] . Male gender, the presence of liver metastases and an increasing number of organs involved were all independent predictors for poor outcome [6] . Patient's performance status is also a critical prognostic variable. Searching for the primary site in patients with rapidly progressing disease and poor performance status is not indicated when best supportive care is the only treatment option. 
biology of CUP
The primary site may either remain microscopic and escape clinical detection or disappear after seeding the metastases [7] [8] [9] . If only one tumor site is identified, it may also represent an unusual primary tumor mimicking metastatic disease. Advances in the understanding of the basic biology of CUP may have a direct impact on clinical care [10] . One can regard CUP as common metastases of an unrecognized primary. In this case diagnostic evaluation should concentrate on the identification of the primary origin of the tumor. Its identification would lead to a disease-directed treatment and a better defined prognosis. Consequently, research should focus on developing tools for better detection and/or classification of primary tumors such as MRI or PET. However, some studies have shown that the prognosis is not better when the primary tumor has been identified [11, 12] . In contrast, when we take into account the concept of a specific biology of CUP, the search for a primary is of minor importance and diagnostic evaluation should focus on the detection of specific biochemical and molecular targets. In fact, CUP are characterized by an early dissemination and an unpredictability of metastatic pattern and aggressiveness [13] . CUP primaries, when found, tend to spread in a manner different from that of known primaries of the same organ. Lung cancer presenting as known primary involves the bones in 30-50%, while presenting as CUP the osseous involvement is 5%. Pancreatic cancer presenting as CUP has as 4-fold higher incidence of affecting bones, whereas prostate cancer presenting as CUP has a 3-fold less incidence of affecting bones compared with known primaries [14] .
searching for the primary tumor site
The costs, in terms of time and money, as well as the final benefit in the outcome of the patients have to be taken into consideration. In oncology, predictions about prognosis and decisions about therapy are mainly based on knowledge of the primary site. However, a critical review of the literature does not indicate the value of an exhaustive and expensive search for the primary tumor site. It is only recommended to identify treatable and in some cases potentially curable subsets of patients with CUP. In the past, approximately 5-10% of patients with CUP benefited from a specific treatment approach. However, new drugs are now available and palliative chemotherapy is recommended for most solid tumors, even in advanced stage. More patients benefit now from diseasedirected treatments. Furthermore, even when no beneficial tumor-specific therapeutic option exists, patients and their physician often desire to know the source and type of neoplasm. The absence of a primary generates anxiety and results in feelings that the evaluation has been inadequate. There is also an unproven feeling that the prognosis can be improved when the primary is identified [12] . With the increasing availability of new diagnostic modalities and better palliative treatment options, physicians must determine how much diagnostic workup is sufficient before accepting a diagnosis of CUP [9] . It is important to define a practical guideline for the diagnostic work-up of patients suffering from CUP but, unfortunately, not anyone has been prospectively evaluated.
A careful pathologic evaluation plays an increasing role in searching for the primary tumor site. Immunohistochemical techniques allow the physician to clarify tumor subtypes in up to 40% of patients [15] . Cytokeratins 7 and 20 and thyroid transcription factor are some of the useful immunohistochemical markers in adenocarcinoma. Potentially treatable or curable tumors (i.e. breast cancer, prostate cancer, lymphomas, germ cell tumors, Ewing's sarcoma) have to be ruled-out by specialized modern pathologic techniques. Molecular identification of tumor origin is a successful new approach [8, 16] . The use of gene expression data generated from micro-array technology may also help to identify the primary site in patients with CUP [17, 18] .
All patients should have an evaluation including a complete history, physical examination and basic blood and biochemistry survey. It is very important to point out that an appropriate evaluation begins with a thorough history [19] . A review of the past medical history should include questions regarding prior surgeries for 'benign' skin lesions and moles because further investigation may reveal these to be the source of the current metastatic disease. Family history of breast, ovarian or colorectal cancers may suggest the presence of an underlying heritable cancer syndrome and an increased risk for specific malignancies. Also a social history focused on prior exposures (such as tobacco or asbestos) and risk factors for HIV infection may suggest an underlying risk for certain tumors. Basic laboratory tests will not identify the primary tumor but may provide information regarding potential unrecognized sites of metastatic disease. They offer also an assessment of organ function that can be used to predict the patient's ability to tolerate chemotherapy.
If a specific clinicopathological entity is not suspected, all patients should have a standard diagnostic work-up including at least urinalysis, fecal occult blood test, chest X-ray and CT of the abdomen and pelvis [20] (Table 1) . Assessment of serum alpha-foetoprotein (AFP), human chorionic gonadotropin (HCG) and prostate-specific antigen (PSA) is suggested in male patients to exclude potentially curable extragonadal germ cell tumor or prostate cancer amenable to hormone treatment. The use of tumor markers except AFP, HCG and PSA in this special circumstance is discouraged because • A specific clinicopathological entity is suspected or the predominant site of disease will guide radiodiagnostic procedures • All the other patients should have a standard evaluation including at least urinalysis, fecal occult blood test, chest-X-ray and CT of the abdomen and pelvis. A CT of the thorax and a PET scan may also be useful of a low specificity [21] . Furthermore, no association between a particular marker elevation and response to therapy or survival has been observed. Further evaluation and endoscopies should be sign-or symptom-guided. The diagnostic work-up in specific clinicopathological entities is discussed later in this review (Tables 2-3) .
CT of the chest
Although CT of the chest is not part of the standard evaluation [20] , one can discuss its role in CUP. Chest X-ray is able to differentiate between primary and secondary malignancies in only one third of the patients [22, 23] . CT of the chest can provide several useful pieces of information [2, 3] . Involvement of the mediastinum is best evaluated by CT. It can also determine the extent of the metastatic disease and it may provide guidance in selecting the optimal site for biopsy. Furthermore, lung cancer is one of the most common identifiable primary tumors that present with CUP. Consequently, a CT thorax is usually performed.
positron emission tomography PET using 18 F-fluorodeoxyglucose ( 18 F-FDG) merits also further evaluation [24] . 18 F-FDG PET allows whole-body screening.
18 F-FDG PET can correctly identify a primary site of disease in some patients. In particular, it may be helpful in localizing head and neck tumors in patients with a cervical lymphadenopathy from an unknown primary [25] [26] [27] [28] [29] [30] [31] [32] . Some investigators have observed that the false positive rate of PET in this setting may be extremely high [33] . Even though whole-body 18 F-FDG PET has several advantages over conventional imaging techniques, there are some limitations. 18 F-FDG is excreted by the kidneys and the ability to detect tumors in the urinary tract may be limited. Physiologic uptake in the digestive tract may mimic a primary tumor leading to unnecessary gastrointestinal endoscopies. 18 F-FDG uptake may be low in well-differentiated slowly growing tumors such as prostate cancer or neuroendocrine tumors. 18 F-FDG PET is also limited by spatial resolution for the detection of very small primary tumors. The likelihood of finding a primary tumor in patients who already underwent extensive work-up with CT, MRI, US and endoscopy seems low. Of course, the sensitivity of PET depends on the number of other imaging procedures done in addition to standard evaluations, defining CUP. Although most investigators have performed PET after a thorough negative diagnostic work-up, its high sensitivity could indicate that it should be used as a first-line modality in order to guide the diagnostic procedures (Figures 1-4) . From the patients point of view, a one-day non-invasive procedure is usually preferable to repeated visits to the hospital, especially when the single procedure is more effective, as shown in two recent studies [34, 35] . Both retrospective studies included only a few patients with cervical lymph node metastases but a high number of patients with brain metastases. They reported an advantage of PET over CT in particular in the detection of lung cancer and pancreaticobiliary system tumors. However, the performance of PET can be overestimated compared to conventional imaging methods because PET scan were analyzed by a team of experienced physicians while conventional imaging methods were performed in different locations and conditions, not standardized and their results were not analyzed by the same radiologists. PET was also superior to mammography in the detection of breast cancer. False positive findings were observed in the digestive tract and in the head and neck region [34] . No conclusion can be drawn from these retrospective studies about the cost-effectiveness of using PET as a first-line imaging procedure in patients with CUP.
The potential role of PET is not only to identify an occult primary. It can direct a biopsy of other metastatic lesions when a larger biopsy is needed for further pathologic evaluation avoiding sometimes a more invasive procedure. PET can also improve the staging of the disease in showing more advanced disease than the conventional investigations. Sometimes a specific histologic pattern with a particular anatomic distribution identifies a clinical presentation with still a curative approach. For example, an isolated lymph node metastasis of melanoma without an obvious primary can be cured by lymphadenectomy. In patients with metastases evident only in one site based on conventional imaging technique, PET may indicate who is not candidate for a local treatment by detecting further unknown metastatic sites.
the radio-diagnostic evaluation of different clinicopathological entities
Optimal pathologic evaluation is critical because it may allow identification of the primary site, of specific cancer types (e.g., lymphomas) and of patients subtypes with specific treatment implications (e.g., poorly differentiated neuroendocrine tumors). Patients should be evaluated based on one of five histologies: undifferentiated neoplasm, well or moderately differentiated adenocarcinoma, squamous cell carcinoma, poorly differentiated carcinoma/adenocarcinoma and carcinoma with neuroendocrine differentiation. The localization of the metastasis and other clinical information will guide the radiodiagnostic work-up in each of these histologies [36] .
poorly or undifferentiated neoplasm of unknown primary This is a group of patients where the pathologist is unable to distinguish a general category of neoplasm (carcinoma, lymphoma, melanoma, sarcoma, neuroendocrine tumors, germ cell tumor, melanoma). It accounts for less than 5% of all CUP. Specialized modern pathologic techniques can now aid in tumor characterization. This is extremely important because many patients have responsive tumors. Further pathologic evaluation revealed in older studies that 34-66% of poorly differentiated or anaplastic neoplasms are lymphomas [37] . Most of the remaining tumors were poorly differentiated carcinoma; other tumors, including melanoma and sarcoma, accounted for less than 15% of all patients. The most common cause of a nonspecific light microscopic diagnosis is an inadequate biopsy specimen. Radiodiagnostic procedures may allow identification of sites where a larger biopsy can be obtained more easily. Immunohistochemistry and other specialized modern pathologic techniques should be routinely applied in poorly differentiated cases to exclude chemosensitive and potentially curable tumors (i.e. lymphoma and germ cell tumors). Close cooperation between the pathologist and clinician optimizes the chances of making a specific diagnosis in patients with CUP [37] . All patients should have a standard diagnostic work-up at baseline including CT of the thorax and CT of the abdomen and pelvis. The role of imaging techniques is mainly staging and response evaluation in this group of patients.
well or moderately differentiated adenocarcinoma of unknown primary
About 50% of all patients with CUP fall in this category. Most patients are elderly and have multiple sites of metastases including liver, lungs and bones. The primary site is only identified in 15-20% of patients during life in older studies prior to the availability of CT [38] . The most common primary identified at autopsy were lung and pancreas (about 40% of cases) followed by other gastrointestinal sites (stomach, colon and liver). Adenocarcinoma of the breast, prostate and ovary are only rarely encountered in this group of patients [14] . Dosage of PSA tumor marker level should be performed in all men. In 32-35% of patients a CT of the thorax or of the abdomen and pelvis can identify a primary [2, 3] . CT of the thorax and of the abdomen and pelvis should be performed in all patients. Extensive use of other radiodiagnostic procedures is not recommended because it rarely identifies the primary. Furthermore, many of these patients have widespread metastases and poor performance status at the time of diagnosis, with a median survival time of only a few months. Searching for the primary site in patients with rapidly progressing disease and poor performance status is questionable because supportive care is the only treatment option. However, there are subsets of patients with a more favorable outcome that can be identified. Chemotherapy has also improved considerably in the last years and many patients are now candidates for chemotherapy because they have a reasonable expectation to benefit from treatment in term of quality of life and/or survival. A careful histological evaluation allows frequently to guide the radiodiagnostic work-up.
Several clinical situations merit further discussion because the patient receives a specific treatment.
breast cancer
Breast cancer should be suspected in women who have axillary lymph node involvement by adenocarcinoma, even if the mammography and US of the breast are normal. The sensitivity of the mammography to detect an unknown primary in this clinical situation is around 20% [39] . MRI of the breast is useful in identifying a primary site in some of these patients [40] . MRI should be added before defining the breast as occult [40] . Some guidelines suggest that a mammography should be done in all women suffering from metastatic adenocarcinoma or poorly differentiated tumors. Unfortunately, the specificity of mammography in an unselected patient population is low [22, 41] . However, we suggest considering mammography in all women according to clinical presentation because of the major impact on patient management when the primary is found in the breast.
primary peritoneal carcinomatosis
Some women have diffuse peritoneal involvement by an adenocarcinoma. Although a carcinoma from the gastrointestinal tract, lung or breast can occasionally spread in this fashion, this presentation is most typical for ovarian carcinoma. Serum CA125 tumor marker level should be determined [37] . Some of these women do not have evidence of an ovarian tumor or other obvious primary at laparotomy. This syndrome is now called primary peritoneal carcinomatosis. The clinical features are similar to ovarian cancer or abdominal carcinomatosis. It can be seen in women who previously had their ovaries removed, in particular in patients harboring BRCA1 mutations.
prostate cancer
In men with skeletal metastases, a metastatic prostate carcinoma should be suspected in particular when the patient presents an adenocarcinoma involving predominantly the bones, when the metastases are blastic or when the serum PSA or acid phosphatase level is increased. Some men have more unusual radiological presentations and the diagnosis is only suggested by tumor staining for PSA [42, 43] . Usually they have metastases in the lung, in mediastinal lymph nodes or in upper abdominal lymph nodes but they do not have involvement of pelvic lymph nodes or of the bones.
colon cancer
Colon cancer has to be excluded in patients presenting only liver metastases. A colonoscopy should be done even if fecal occult blood tests are negative.
only one identified metastasis
Local treatment should be administered to the unusual patient who presents with tumor at only one identifiable site. A PET may be useful to exclude more extensive metastatic spread. Some of these patients have prolonged survival after local therapy particularly those who present with a sole metastasis in an isolated peripheral lymph node group.
Sometimes the predominant site of disease will guide further diagnostic work-up.
pleural effusion
In the case of pleural effusion, a CT of the thorax is indicated to search for a primary lung cancer. A bronchoscopy will be done if the CT of the thorax shows abnormalities suggestive to be the primary tumor. In a woman, breast cancer, ovarian cancer or primary peritoneal carcinomatosis should also be excluded.
lung metastases
Most patients with multiple lung lesions suffer from lung cancer. A CT of the thorax and a bronchoscopy should be done but a CT of the abdomen and pelvis should also be performed in order to exclude a primary outside of the lung.
bone metastases
A CT of the thorax and of the abdomen and pelvis will identify the primary in most cases. In men, in particular when metastases are osteoblastic, prostate cancer is frequently the origin (see above). Digital rectal examination and dosage of PSA serum level should be done. In a woman osteoblastic metastases are most times related to a primary breast cancer. Clinical examination of breast, a mammography, an ultrasound and an IRM of the breast should be performed. A bone scintigraphy will guide further imaging studies (radiography, CT, IRM) of the bones. Prophylactic interventions and palliative systemic treatments are now available decreasing the morbidity associated with bone metastases.
CNS metastases
A CT of the thorax is indicated because an asymptomatic primary lung tumor is frequently identified.
squamous cell carcinoma
This histology represents only 15% of unknown primary carcinoma. Appropriate evaluation of these patients is essential because effective treatment is available for certain clinical syndromes.
cervical and supraclavicular lymph node metastases
Most patients are middle-aged or elderly and frequently have abused tobacco or alcohol. Upper or mid-cervical lymph nodes are usually related to a primary tumor in the head and neck region. All patients should undergo a thorough search for a primary site in the head and neck region, including a CT of the head and neck and panendoscopy (laryngoscopy, bronchoscopy and esophagoscopy). Routine blind biopsies of common potential primary sites, including the base of the tongue, piriform sinus and tonsils and of any suspicious mucosal area are performed. Ipsilateral or bilateral tonsillectomy are often performed because they will be found to harbor an occult primary in 10-25% of patients [30] . 18 F-FDG PET may be useful in identifying a primary tumor in the head and neck area [29, 31] . Some studies indicate that 18 F-FDG PET identifies an occult primary site in the head and neck area in approximately one-third of patients [26, 28, 30, 32] . However, the real sensitivity of PET in an unselected patient population after an appropriate standard evaluation including ear-nose-throat endoscopy remains unknown. 18 F-FDG PET has also some limitations. 18 F-FDG uptake can be variable in the tonsils, adenoid, salivary glands and in muscles of the head and neck which can render image analysis difficult. False-positive and false-negative findings can result under these circumstances [24, 34] . When no primary site is identified and lymph node resection alone is used as the primary treatment modality, a primary tumor in the head and neck subsequently becomes obvious in 20-40% of patients [37] .
Lower cervical or supraclavicular lymph node involvement is frequently related to a primary lung cancer. A CT thorax and bronchoscopy should be performed. When the CT of the thorax is negative, a primary tumor of the oesophagus or of the head and neck region should be excluded by a panendoscopy.
inguinal lymph nodes
Almost all patients have a primary tumor identifiable in the perineal region. Identification of a primary site in the vulva, vagina, cervix and anus is important because even after spread to regional nodes a curative approach remains possible. A careful examination of the vulva, vagina and cervix in women or the penis and scrotum in men is indicated.
A colposcopy should always be performed in women. Digital rectal examination and anoscopy is also indicated to exclude a primary in the anorectal area.
bone metastases
A CT of the thorax should be performed. If the CT is negative, a panendoscopy should be done. A bone scintigraphy will guide further imaging studies (radiography, CT, IRM) of the bones. Prophylactic interventions and palliative systemic treatments are now available decreasing the morbidity associated with bone metastases.
other sites
Most times these patients have an occult primary lung cancer. A CT of the chest and a bronchoscopy should be performed. Other rare presentations include primary tumors from the head and neck, esophagus, anus and skin.
poorly differentiated carcinoma
About 30% of all patients with an unknown primary have poorly differentiated carcinoma or poorly differentiated adenocarcinoma. Clinical and pathological evaluation is critical because some patients can be cured by cisplatin-based chemotherapy. Tumor location is the most useful clinical feature in predicting response to therapy and survival [44] . Patients have a rapid progression of symptoms and objective evidence of rapid tumor growth. Lymph nodes in the mediastinum and retroperitoneum are more frequently among the predominant sites of disease compared with well differentiated adenocarcinoma. The median age of this group of patients is also younger although a wide age range has been observed. CT of the chest and abdomen should be performed in all patients because of the frequency of mediastinal and retroperitoneal involvement. Significant increase of serum levels of HCG and alphafetoprotein suggest the diagnosis of germ cell tumor. A scrotal ultrasonography should be performed in particular in young men.
Most patients with multiple lung lesions suffer from a primary lung cancer. A CT of the abdomen and pelvis is performed to search for a primary in this region. It is also important to exclude testicular cancer in a young man (HCG and AFP serum level, scrotal ultrasound) or unsuspected gestational choriocarcinoma in a young woman (history of recent pregnancy, spontaneous abortion or missed menstrual periods, HCG serum level).
In the case of pleural effusion, a biopsy allows to exclude mesothelioma. A primary lung cancer can be detected by a CT of the thorax. In women, it is also indicated to perform a mammography (breast cancer?), a gynecological examination and an ultrasound of the pelvis (ovarian cancer?).
The most frequent causes of malignant peritoneal effusions have yet been discussed in the section about well and moderately differentiated adenocarcinoma.
The possibility of an unusual primary tumor mimicking metastatic disease should be considered when only one site of neoplasm is identified. Merkel cell tumors, skin adnexal tumors or sarcomas can have this kind of presentation.
Patients with undifferentiated neuroendocrine tumors with very limited involvement at only one site treated with only local modalities can have a good long term outcome [37] . Radio-imaging studies (CT of the thorax, CT of the abdomen and pelvis, bone scintigraphy) are indicated to exclude the presence of other tumor sites.
The diagnostic work-up for patients suffering from poorly differentiated adenocarcinoma is the same than for patients with well or moderately differentiated adenocarcinoma.
carcinomas with neuroendocrine differentiation
An octreoscan (well differentiated tumors) or a PET-scan (poorly differentiated tumors) may be useful to search for the primary but further prospective evaluations of the impact on patient management and outcome are needed.
conclusions and perspectives
Unfortunately, no practical guideline for the diagnostic work-up of patients suffering from CUP has been prospectively evaluated. A reasonable clinical and pathologic evaluation of these patients and their tumors is indicated. The methodology used for the evaluation of radio-imaging techniques is rather poor and results from older studies give little useful information on the accuracy of modern radiological equipments. Furthermore, the study population has rapidly changed because of improvements in pathology allowing more frequently the identification of the primary tumor site. With all these limitations in mind, we conclude after a critical review of the literature, that an integrated approach taking into account history, clinical examination, histology and sometimes tumor markers is indicated when searching for a primary tumor site. Sometimes specific clinical presentations can be identified and will guide directly the diagnostic work-up. If a specific clinicopathological entity is not suspected, all patients should have a standard diagnostic work-up including at least urinalysis, fecal occult blood test, chest X-ray and CT of the abdomen and pelvis. Although CT of the thorax is not part of the standard evaluation, it is usually performed. Imaging techniques are not only useful for searching the primary tumor site but can also sometimes guide a biopsy. They are also performed to define extend of disease and to monitor response to treatment. In the future, a whole-body PET/CT may be used as first-line imaging procedure guiding further radio-diagnostic evaluation. Prospective studies with an improved methodology (definition of study population, definition of gold standard, interpretation of new imaging techniques and reference studies both by experienced investigators, etc.) are needed to better evaluate the role and cost-effectiveness of imaging techniques in CUP. A prospective validation of practical guidelines is also needed. 
